In the CATCHAML (CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia) trial (NCT04318678), researchers are evaluating the safety and tolerability of autologous CD123-directed CAR T cells in patients younger than 21 years with CD123-expressing hematologic malignancies, including BPDCN. The gene discussed is IL3RA; the disease is hematologic disorder.